Johnson & Johnson vs Ross Stores
Side-by-side comparison of AI visibility scores, market position, and capabilities
FY2024 Sales: $88.8B (+4.3%) | Net Profit: $14.1B (+5.6%) | EPS: $5.79 | Adjusted EPS: $9.98 | FY2025 Guidance: Operational Sales Growth 2.5-3.5%, Adj EPS $10.75-$10.95 (+8.7% midpoint)
About
Johnson & Johnson is one of the world's largest healthcare companies, founded in 1886 by brothers Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson in New Brunswick, New Jersey, where the company remains headquartered. Established to manufacture ready-to-use surgical dressings at a time when post-operative infection was a leading cause of surgical mortality, J&J was built on the scientific principles of antiseptic surgery advocated by Joseph Lister. The company trades on the NYSE under ticker JNJ and has evolved over 135+ years from a consumer health products manufacturer into a focused MedTech and pharmaceutical enterprise, completing the spinoff of its consumer health segment (Kenvue) in 2023.\n\nJohnson & Johnson now operates through two segments: Innovative Medicine and MedTech. Innovative Medicine encompasses oncology, immunology, neuroscience, infectious disease, and cardiovascular pharmaceutical products — including blockbusters Darzalex, Stelara, Tremfya, and Rybrevant. The MedTech segment includes surgical robotics (Ottava platform in development), electrophysiology (Abiomed, Biosense Webster), orthopedics (DePuy Synthes), and surgery systems, serving hospitals and surgical centers worldwide. Following the Kenvue separation, J&J is a pure-play healthcare technology and pharmaceutical company with significantly higher growth and margin profiles than its historical blended consumer-pharma-medtech structure.\n\nJohnson & Johnson reported FY2024 sales of $88.8 billion, up 4.3% year over year, with net profit of $14.1 billion, up 5.6%. The company's Innovative Medicine segment continues to grow driven by oncology and immunology portfolio strength, while MedTech benefits from procedure volume recovery and robotic surgery adoption. J&J's scale, R&D pipeline depth, and global commercial infrastructure — spanning more than 60 countries — position it as one of the two or three most consequential healthcare enterprises globally, with a patent portfolio, clinical trial network, and regulatory expertise that are nearly impossible to replicate.
Dublin CA largest US off-price retailer (NASDAQ: ROST) at $21.1B FY2024 sales (+3.7%), $2.1B net income; 2,273 stores expanding to 2,900 Ross + 700 dd's target competing with TJX Companies for off-price apparel shoppers.
About
Ross Stores, Inc. is a Dublin, California-based off-price variety retailer — publicly traded on NASDAQ (NASDAQ: ROST) as an S&P 500 Consumer Discretionary component — operating two retail banners: Ross Dress for Less (name-brand and designer apparel, footwear, and home fashion at 20-60% below department store prices) and dd's DISCOUNTS (20-70% below moderate department store prices for more budget-conscious shoppers) through approximately 107,000 employees. In fiscal year 2024, Ross Stores reported $21.1 billion in total sales (up 3.7% year-over-year), net earnings of $2.1 billion, and EPS of $6.32 (versus $5.56 in fiscal 2023), opening 89 new stores (75 Ross, 14 dd's) to end FY2024 with 2,205 total stores. As of 2025, Ross operates 2,273 stores across 44 states, Washington D.C., Guam, and Puerto Rico with long-term expansion targets of 2,900 Ross Dress for Less and 700 dd's DISCOUNTS locations. Founded in 1950 as a small department store chain in San Bruno, California, Ross transformed into an off-price retailer in 1982 under new management and grew into the largest US off-price retailer by revenue. The company sources merchandise through buying offices in New York City, Los Angeles, and Boston, accessing manufacturer overruns, retail liquidations, and closeout opportunities from thousands of vendors and brand partners. Seven distribution centers support the nationwide store network.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.